Product Pipeline
MPL adjuvant is currently undergoing Phase III clinical trials in Europe for use in allergy vaccines. These vaccines are also marketed and sold by Allergy Therapeutics on a named-patient basis in Germany. Phase II clinical trial data suggest that adding MPL adjuvant may result in faster response to treatment, fewer treatments with decreased dosages, and a higher response rate.

Related News
10/29/2001 Corixa and Wyeth Lederle Vaccines amend agreement
10/27/1999 MPL launched in Germany for patient-specific use
06/10/1999 Corixa to acquire Ribi
A business overview as well as information on Corixa's partners, management team, employment opportunities, and company contacts.
Corixa's near-term products and adjuvant for research applications.
Product pipeline, therapeutic areas of focus, products, technology platforms, and publications.
Company reports, stockholder letter, events calendar, stock quote, analyst list, and materials request.
Current and archived company press releases.
Product pipeline, therapeutic areas of focus, products, technology platforms, and publications.